
    <rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
      <channel>
        <title>Articles tagged with CBER from Medical Marketing and Media</title>
        <link>http://www.mmm-online.com/cber/topic/9673/</link>
        <description>Articles tagged with CBER from Medical Marketing and Media</description>
        <itunes:author>MMM</itunes:author>
        <itunes:subtitle></itunes:subtitle>
        <itunes:summary></itunes:summary>
        <itunes:owner>
            <itunes:name></itunes:name>
            <itunes:email>mmmsubs@haymarketmedia.com</itunes:email>
        </itunes:owner>
        <itunes:category text="BUSINESS">
            <itunes:category text="BUSINESS NEWS" /> 
        </itunes:category> 
        <itunes:image href='http://media.haymarketmedia.com/images/32/MMM_logo_28402_31022.gif'></itunes:image>
        <itunes:explicit>no</itunes:explicit>
  
        <item>
          <title>Sequester cuts could snarl approvals for years</title>
          <description>With sequester cuts taking effect and no sign of a deal to end them in sight, FDA stands to lose 5% of its 2013 budget—though coming five months into the Federal fiscal year, it will feel more like 9%—and while the agency has said it has no plans at present for layoffs, it&apos;s certain the approvals process will slow as the agency absorbs the loss.</description>
          <link>http://www.mmm-online.com/sequester-cuts-could-snarl-approvals-for-years/article/283295/</link>
          <pubDate>Wed, 06 Mar 2013 19:20:47 GMT</pubDate>
          <itunes:summary>With sequester cuts taking effect and no sign of a deal to end them in sight, FDA stands to lose 5% of its 2013 budget—though coming five months into the Federal fiscal year, it will feel more like 9%—and while the agency has said it has no plans at present for layoffs, it&apos;s certain the approvals process will slow as the agency absorbs the loss.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Dendreon draws CBER letter for Provenge professional marketing</title>
          <description>The Center for Biologics Evaluation and Research hit Dendreon with an untitled letter for false and misleading professional marketing materials for its prostate cancer treatment Provenge.</description>
          <link>http://www.mmm-online.com/dendreon-draws-cber-letter-for-provenge-professional-marketing/article/176708/</link>
          <pubDate>Tue, 10 Aug 2010 18:37:09 GMT</pubDate>
          <itunes:summary>The Center for Biologics Evaluation and Research hit Dendreon with an untitled letter for false and misleading professional marketing materials for its prostate cancer treatment Provenge.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
      </channel>
    </rss>  
  